Eszter Vamos
Pecs, BA 7624, Hungary
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Selective MIF Enolase Inhibitor TE-91 Regulates M1 Polarization and Associated Metabolic Reprogramming.
Journal: Antioxidants (Basel, Switzerland)
Published: April 18, 2026
Dual Inhibition of PARP and Akt Induces Metabolic Collapse and Apoptosis in Breast Cancer Cells.
Journal: Cancers
Published: October 31, 2025
Gold Nanoparticles Disrupt Mitochondrial Activity in Hypothalamic POMC Cells: Implications for Energy Homeostasis.
Journal: Nanomaterials (Basel, Switzerland)
Published: July 31, 2025
MIF tautomerase inhibitor TE-11 prevents inflammatory macrophage activation and glycolytic reprogramming while reducing leukocyte migration and improving Crohn's disease-like colitis in male mice.
Journal: Frontiers in immunology
Published: January 09, 2025
Cardiac effects of OPA1 protein promotion in a transgenic animal model.
Journal: PloS one
Published: February 28, 2024
Highly Selective MIF Ketonase Inhibitor KRP-6 Diminishes M1 Macrophage Polarization and Metabolic Reprogramming.
Journal: Antioxidants (Basel, Switzerland)
Published: July 27, 2023
Synthesis and evaluation of a new class of MIF-inhibitors in activated macrophage cells and in experimental septic shock in mice.
Journal: European journal of medicinal chemistry
Published: October 19, 2022
Distinct Uptake Routes Participate in Silver Nanoparticle Engulfment by Earthworm and Human Immune Cells.
Journal: Nanomaterials (Basel, Switzerland)
Published: July 28, 2022
Tetralone derivatives are MIF tautomerase inhibitors and attenuate macrophage activation and amplify the hypothermic response in endotoxemic mice.
Journal: Journal of enzyme inhibition and medicinal chemistry
Published: July 06, 2021
Cytostatic Effect of a Novel Mitochondria-Targeted Pyrroline Nitroxide in Human Breast Cancer Lines.
Cytostatic Effect of a Novel Mitochondria-Targeted Pyrroline Nitroxide in Human Breast Cancer Lines.
Journal: International journal of molecular sciences
Published: June 30, 2021
Olaparib: A Clinically Applied PARP Inhibitor Protects from Experimental Crohn's Disease and Maintains Barrier Integrity by Improving Bioenergetics through Rescuing Glycolysis in Colonic Epithelial Cells.
Journal: Oxidative medicine and cellular longevity
Published: April 18, 2021
Showing 1-11 of 11
Last Updated: 09/26/2026